← Back to headlines
Omeros Projects Q3 2026 Interest Expense and Advances YARTEMLEA
Omeros has outlined an estimated interest expense of approximately $6.5 million for Q3 2026 while also advancing $287,000 in NTAP for its drug YARTEMLEA.
13 Aug, 05:18 — 13 Aug, 05:18
Sources
Showing 1 of 1 sources
